Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial
- PMID: 21960168
- DOI: 10.1038/ki.2011.191
Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial
Abstract
Patients with steroid-resistant focal segmental glomerulosclerosis (FSGS) may benefit from treatment with calcineurin inhibitors. A National Institutes of Health-funded FSGS multicenter study has suggested that a combination of mycophenolate mofetil and oral dexamethasone pulses was equivalent to cyclosporine. However, since the study was underpowered, one cannot draw firm conclusions from this study. The FSGS trial underscores that FSGS is not one disease and that better predictors of outcome and response to therapy are needed.
Comment on
-
Clinical trial of focal segmental glomerulosclerosis in children and young adults.Kidney Int. 2011 Oct;80(8):868-78. doi: 10.1038/ki.2011.195. Epub 2011 Jul 6. Kidney Int. 2011. PMID: 21734640 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
